| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | -0.037 | 0.8 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.0082 | 0.8 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.0085 | 0.8 |